Table 3.
Patients characteristics of the articles.
| Authors/Year of Publication | No. of Patients | Age | FEV1 % Pred | COPD Stage | Duration of Medication | Duration of Monitoring |
|---|---|---|---|---|---|---|
| Effective | ||||||
| Hataji 2013 [42] | 23 | 69.7 | 64.5 | I–IV | 4 W | 4 W |
| Watz 2014 [39] | 129 | 61.4 | 64 | II, III | 3 W | 1 W |
| Minakata 2015 [43] | 21 | 70.7 | 52.6 | I–IV | 6 W | 2 W |
| Watz 2017 [40] | 127 vs. 123 | 62.6 vs. 62.1 | 60.3 vs. 61.0 | II, III | 4 W | 1 W |
| Minakata 2019 [41] | 184 | 72.8 | 52.6 | II, III, IV | 6 W | 2 W |
| Kamei 2019 [44] | 22 vs. 22 | 72.3 vs. 70.9 | 60.1 vs. 57.6 | II, III | 8 W | 1 W |
| Hirano 2019 [45] | 14 | 72.1 | 55.6 | II, III, IV | 8 W | 2 W |
| Tsujimura 2019 [46] | 12 | 71.5 | FEV1% 34.5 | III, IV | 4, 12 W | 2 W |
| Dependent on indicators | ||||||
| Beeh 2014 [31] | 112 | 60.3 | 56.7 | II–III | 3 W | 1 W |
| Nishijima 2015 [48] | 18 | 74.2 | 55.2 | II, III, IV | 12 W | 1 W |
| Watz 2016 [47] | 194 | 62.8 | 61.6 | I–IV | 3 W | 1 W |
| Ineffective | ||||||
| O’Donnell 2011 [49] | 89 | 62.8 | 61.2 | I, II, III | 3 W | 5 days |
| Troosters 2014 [50] | 238 vs. 219 | 61.2 vs. 62.3 | 65.6 vs. 65.8 | II | 24 W | 1 W |
| Ichinose 2018 [51] | 184 | 72.8 | 52.6 | II, III, IV | 6 W | 2 W |
| Troosters 2018 [52] | 65 vs. 67 vs. 72 | 64.2 vs. 65.4 vs. 64.9 | 56 vs. 57 vs. 59 | I–IV | 12 W | 1 W |
FEV1 % Pred, forced expiratory volume in one second % of predicted; W, week(s).